Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Core Insights - Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, aimed at treating locally advanced or metastatic cutaneous melanoma after standard immunotherapy [1][3] - WTX-124 is a conditionally activated interleukin 2 (IL-2) therapy designed to enhance anti-tumor immune responses while minimizing systemic toxicities [2][4] - The Fast Track Designation allows for expedited development and frequent interactions with the FDA, potentially leading to priority review and accelerated approval [3] Company Overview - Werewolf Therapeutics is focused on developing therapeutics that stimulate the immune system for cancer and immune-mediated conditions, leveraging its proprietary PREDATOR® platform [4] - The company is advancing WTX-124 and WTX-330, both conditionally activated IL-2 and IL-12 INDUKINE molecules, for the treatment of solid tumors [4] - WTX-124 is currently being evaluated in a Phase 1/1b clinical trial, including both single-agent and combination arms with pembrolizumab [2][3]